Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression

Kang Hun Lee, Ena Wang, Mai Britt Nielsen, John Wunderlich, Steven Migueles, Mark Connors, Seth M. Steinberg, Steven A. Rosenberg, Francesco M. Marincola

Research output: Contribution to journalArticle

246 Citations (Scopus)

Abstract

Although in vitro sensitization assays have shown increased melanoma Ag (MA)-specific CTL reactivity after vaccination with MA peptides, clinical responses have been uncommon. This paradox questions whether data obtained from the in vitro stimulation and expansion of T cells lead to an overestimation of the immune response to vaccines. Using HLA/peptide tetramer (tHLA), we enumerated MA-specific T cell precursor frequency (TCPF) directly in PBMC from 23 melanoma patients vaccinated with gp100:209-217(210M) (g209- 2M) peptide. Vaccine-specific TCPF was higher in postvaccination PBMC from seven of seven patients treated with peptide alone anti four of five patients treated with peptide plus IL-12 (range of postvaccination TCPF, 0.2-2.4% anti 0.2-2.5%, respectively). The increased TCPF correlated with enhanced susceptibility to in vitro stimulation with the relevant epitope. Paradoxically, no increase in postvaccination TCPF was observed in most patients who had been concomitantly treated with IL-2 (1 of 11 patients; range of postvaccination TCPF, 0.02-1.0%), a combination associated with enhanced rates of tumor regression. The lack of increase in TCPF seen in these patients corresponded to inability to elicit expansion of vaccine- specific T cells in culture. This study shows that a peptide-based vaccine can effectively generate a quantifiable T cell-specific immune response in the PBMC of cancer patients, though such a response does not associate with a clinically evident regression of metastatic melanoma.

Original languageEnglish
Pages (from-to)6292-6300
Number of pages9
JournalJournal of Immunology
Volume163
Issue number11
Publication statusPublished - 1 Dec 1999
Externally publishedYes

Fingerprint

T-Lymphoid Precursor Cells
Vaccination
Vaccines
T-Lymphocytes
Peptides
Melanoma
Neoplasms
Subunit Vaccines
Interleukin-12
In Vitro Techniques
Interleukin-1
Interleukin-2
Epitopes
Cell Culture Techniques

ASJC Scopus subject areas

  • Immunology

Cite this

Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. / Lee, Kang Hun; Wang, Ena; Nielsen, Mai Britt; Wunderlich, John; Migueles, Steven; Connors, Mark; Steinberg, Seth M.; Rosenberg, Steven A.; Marincola, Francesco M.

In: Journal of Immunology, Vol. 163, No. 11, 01.12.1999, p. 6292-6300.

Research output: Contribution to journalArticle

Lee, KH, Wang, E, Nielsen, MB, Wunderlich, J, Migueles, S, Connors, M, Steinberg, SM, Rosenberg, SA & Marincola, FM 1999, 'Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression', Journal of Immunology, vol. 163, no. 11, pp. 6292-6300.
Lee, Kang Hun ; Wang, Ena ; Nielsen, Mai Britt ; Wunderlich, John ; Migueles, Steven ; Connors, Mark ; Steinberg, Seth M. ; Rosenberg, Steven A. ; Marincola, Francesco M. / Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. In: Journal of Immunology. 1999 ; Vol. 163, No. 11. pp. 6292-6300.
@article{fa9d872bdd7f4176bb1b9f77054e9e5f,
title = "Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression",
abstract = "Although in vitro sensitization assays have shown increased melanoma Ag (MA)-specific CTL reactivity after vaccination with MA peptides, clinical responses have been uncommon. This paradox questions whether data obtained from the in vitro stimulation and expansion of T cells lead to an overestimation of the immune response to vaccines. Using HLA/peptide tetramer (tHLA), we enumerated MA-specific T cell precursor frequency (TCPF) directly in PBMC from 23 melanoma patients vaccinated with gp100:209-217(210M) (g209- 2M) peptide. Vaccine-specific TCPF was higher in postvaccination PBMC from seven of seven patients treated with peptide alone anti four of five patients treated with peptide plus IL-12 (range of postvaccination TCPF, 0.2-2.4{\%} anti 0.2-2.5{\%}, respectively). The increased TCPF correlated with enhanced susceptibility to in vitro stimulation with the relevant epitope. Paradoxically, no increase in postvaccination TCPF was observed in most patients who had been concomitantly treated with IL-2 (1 of 11 patients; range of postvaccination TCPF, 0.02-1.0{\%}), a combination associated with enhanced rates of tumor regression. The lack of increase in TCPF seen in these patients corresponded to inability to elicit expansion of vaccine- specific T cells in culture. This study shows that a peptide-based vaccine can effectively generate a quantifiable T cell-specific immune response in the PBMC of cancer patients, though such a response does not associate with a clinically evident regression of metastatic melanoma.",
author = "Lee, {Kang Hun} and Ena Wang and Nielsen, {Mai Britt} and John Wunderlich and Steven Migueles and Mark Connors and Steinberg, {Seth M.} and Rosenberg, {Steven A.} and Marincola, {Francesco M.}",
year = "1999",
month = "12",
day = "1",
language = "English",
volume = "163",
pages = "6292--6300",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression

AU - Lee, Kang Hun

AU - Wang, Ena

AU - Nielsen, Mai Britt

AU - Wunderlich, John

AU - Migueles, Steven

AU - Connors, Mark

AU - Steinberg, Seth M.

AU - Rosenberg, Steven A.

AU - Marincola, Francesco M.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Although in vitro sensitization assays have shown increased melanoma Ag (MA)-specific CTL reactivity after vaccination with MA peptides, clinical responses have been uncommon. This paradox questions whether data obtained from the in vitro stimulation and expansion of T cells lead to an overestimation of the immune response to vaccines. Using HLA/peptide tetramer (tHLA), we enumerated MA-specific T cell precursor frequency (TCPF) directly in PBMC from 23 melanoma patients vaccinated with gp100:209-217(210M) (g209- 2M) peptide. Vaccine-specific TCPF was higher in postvaccination PBMC from seven of seven patients treated with peptide alone anti four of five patients treated with peptide plus IL-12 (range of postvaccination TCPF, 0.2-2.4% anti 0.2-2.5%, respectively). The increased TCPF correlated with enhanced susceptibility to in vitro stimulation with the relevant epitope. Paradoxically, no increase in postvaccination TCPF was observed in most patients who had been concomitantly treated with IL-2 (1 of 11 patients; range of postvaccination TCPF, 0.02-1.0%), a combination associated with enhanced rates of tumor regression. The lack of increase in TCPF seen in these patients corresponded to inability to elicit expansion of vaccine- specific T cells in culture. This study shows that a peptide-based vaccine can effectively generate a quantifiable T cell-specific immune response in the PBMC of cancer patients, though such a response does not associate with a clinically evident regression of metastatic melanoma.

AB - Although in vitro sensitization assays have shown increased melanoma Ag (MA)-specific CTL reactivity after vaccination with MA peptides, clinical responses have been uncommon. This paradox questions whether data obtained from the in vitro stimulation and expansion of T cells lead to an overestimation of the immune response to vaccines. Using HLA/peptide tetramer (tHLA), we enumerated MA-specific T cell precursor frequency (TCPF) directly in PBMC from 23 melanoma patients vaccinated with gp100:209-217(210M) (g209- 2M) peptide. Vaccine-specific TCPF was higher in postvaccination PBMC from seven of seven patients treated with peptide alone anti four of five patients treated with peptide plus IL-12 (range of postvaccination TCPF, 0.2-2.4% anti 0.2-2.5%, respectively). The increased TCPF correlated with enhanced susceptibility to in vitro stimulation with the relevant epitope. Paradoxically, no increase in postvaccination TCPF was observed in most patients who had been concomitantly treated with IL-2 (1 of 11 patients; range of postvaccination TCPF, 0.02-1.0%), a combination associated with enhanced rates of tumor regression. The lack of increase in TCPF seen in these patients corresponded to inability to elicit expansion of vaccine- specific T cells in culture. This study shows that a peptide-based vaccine can effectively generate a quantifiable T cell-specific immune response in the PBMC of cancer patients, though such a response does not associate with a clinically evident regression of metastatic melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0033485764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033485764&partnerID=8YFLogxK

M3 - Article

VL - 163

SP - 6292

EP - 6300

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -